⌕
Liminatus Pharma · LIMN · Nasdaq
Tenet 6 · Weak
Compare
$2.81+4.85%At closeTenet 6 · Weak
$2.81+0.13 (+4.85%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Liminatus Pharma (LIMN) Stock

Liminatus Pharma (LIMN) closed at $2.81 on Nov 19, 2026; its Tenet Score is 6 of 100 against 486 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Close
$2.81
Nov 19, 2026
Market cap
$5.4M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
2.40 – 141.50
low → high
Tenet Score
6/100
Weak · 486 Healthcare peers

Industry: Biological Products, Except Diagnostic Substances · see every company filed here →

Liminatus Pharma, Inc. scores 6/100. Weak. Quality is the soft spot versus 486 Healthcare peers. Insufficient inputs: Tenet 6 is built from 3 of 4 pillars, from 30% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=486
6/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
8
Quality
4
Health
8
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthFGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
18.1×
cap ÷ Jun 30, 2026 book value, Nov 19, 2026 close
P/S
—
no P/S on file
ROE
—
Not reported in the company's filings for this period.
Operating margin
0.0%
fiscal 2025, before interest and tax
Net margin
—
Not reported in the company's filings for this period.
Current ratio
1.12
Jun 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 4y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Liminatus Pharma, Inc.

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocki…

Composite computed Nov 20, 2026 · peer basis: Healthcare (n=486) · every glimpse links to its full section with sources · not investment advice.

Similar-sized companies in Biological Products, Except Diagnostic Substances

The 4 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Liminatus Pharma in?

Liminatus Pharma is in the Healthcare sector and the Biological Products, Except Diagnostic Substances industry.

What is Liminatus Pharma's Tenet Score?

Liminatus Pharma's Tenet Score is 6 out of 100, ranked against 486 Healthcare peers as of Nov 20, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.